Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 2;99(27):e20908.
doi: 10.1097/MD.0000000000020908.

Effects of Gushukang for postmenopausal osteoporosis: A protocol for systematic review and meta-analysis

Guangwei Wang  1 , Liwei Huo  1 , Guocai Chen  2 , Huayong He  1
Affiliations

Effects of Gushukang for postmenopausal osteoporosis: A protocol for systematic review and meta-analysis

Guangwei Wang et al. Medicine (Baltimore). .

Abstract

Background: Postmenopausal osteoporosis (PMO) is one of the most common systemic bone diseases with a high risk of fracture. Traditional herbal formula Gushukang (GSK) has been used to treat PMO. However, there is no systematic review related to GSK for PMO. The object of this work is to evaluate the efficacy and safety of GSK in the management of PMO.

Methods: We will search the PubMed, Embase, MEDLINE, Cochrane Library Central Register of Controlled Trials, China national knowledge infrastructure database (CNKI), Wan fang database, Chongqing VIP information, and SinoMed from their inception to May 2020. All randomized controlled trials (RCTs) of GSK for the treatment of PMO will be included. The improvement of vertebral fracture and bone mineral density (BMD) will be accepted as the primary outcomes. The meta-analyses will be performed by using the RevMan 5.3.

Results: This study will provide a high-quality comprehensive evaluation of the efficacy and safety of GSK for treating patients with PMO.

Conclusion: The conclusion of our systematic review will provide evidence to judge whether GSK is an effective intervention for patients with PMO.

Trial registration number: 10.17605/OSF.IO/MKN3F.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no competing interest in this research.

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Flow chart of study selection.
See this image and copyright information in PMC

References

    1. Eastell R, Szulc P. Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol 2017;5:908–23. - PubMed
    1. Curry SJ, Krist AH, Owens DK, et al. US Preventive Services Task Force. Screening for osteoporosis to prevent fractures: us preventive services task force recommendation statement. JAMA 2018;319:2521–31. - PubMed
    1. Wang Y, Tao Y, Hyman ME, et al. Osteoporosis in China. Osteoporos Int 2009;20:1651–62. - PubMed
    1. Ciubean AD, Ungur RA, Irsay L, et al. Health-related quality of life in Romanian postmenopausal women with osteoporosis and fragility fractures. Clin Interv Aging 2018;13:2465–72. - PMC - PubMed
    1. Teng GG, Curtis JR, Saag KG. Mortality and osteoporotic fractures: is the link causal, and is it modifiable? Clin Exp Rheumatol 2008;26: 5 suppl 51: S125–37. - PMC - PubMed

LinkOut - more resources